Reuben Harris, PhD of University of Minnesota, Minneapolis, MN talks about a clinical impact of APOBEC enzymes. Breast tumor patients with low APOBEC-3B expression levels have a better prognosis than patients with high level of that enzyme, as shown in a retrospective analysis of primary tumor specimens. In addition, dr Harris talks about the analysis of ER-positive tumor samples, where primary tumor APOBEC-3B levels also predicted patient outcomes, with high levels of APOBEC-3B associated with lack of response to tamoxifen and poor outcomes. Recorded at the 2016 National Cancer Research Institute (NCRI) Conference in Liverpool, UK.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest oncology news and updates